Medpace Holdings reported third-quarter 2026 revenue of $716.0 million, up 8.5% from a year earlier, as new business awards and profit grew faster than sales. The Cincinnati-based clinical research organization released the results on October 21 for the quarter ended September 30.
Profit and Backlog Outpace Sales
According to Medpace’s results release, quarterly revenue increased from $659.9 million to $716.0 million. The company converted 23.8% of backlog into revenue during the period.
Net new business awards rose 10.6% to $873.4 million. Backlog at September 30 increased 5.6% to $3.17 billion from $3.00 billion a year earlier, giving investors a view of contracted work that may convert into future revenue.

The chart uses reported revenue from Medpace’s October 21 release. The comparison separates the source publication date from the September 30 quarter-end date.
GAAP net income increased to $137.5 million from $111.1 million. Net margin expanded to 19.2% from 16.8%, while EBITDA rose 16.0% to $172.1 million and the EBITDA margin improved to 24.0% from 22.5%.
Guidance and Buyback Expand
Medpace projected 2026 revenue of $2.835 billion to $2.855 billion, implying growth of 12.0% to 12.8% from 2025. It forecast GAAP net income of $514 million to $524 million, EBITDA of $638 million to $652 million and diluted EPS of $17.97 to $18.32.
The board also replaced an expiring repurchase authorization with a new program allowing up to $1.0 billion of share repurchases through December 31, 2028. The authorization does not require the company to buy any minimum amount.
For comparison across health and life-science businesses, investors can review Danaher’s latest earnings growth, Thermo Fisher’s revenue and margin update and Intuitive Surgical’s procedure trends.
Primary source: Medpace third-quarter 2026 results, published October 21, 2026.




